Analysts expect Medpace Holdings Inc (NASDAQ:MEDP) to report $97.43 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Medpace’s earnings. The lowest sales estimate is $96.20 million and the highest is $98.88 million. Medpace posted sales of $108.24 million during the same quarter last year, which would suggest a negative year over year growth rate of 10%. The business is expected to report its next earnings results on Monday, February 26th.
According to Zacks, analysts expect that Medpace will report full year sales of $97.43 million for the current year, with estimates ranging from $383.20 million to $385.90 million. For the next financial year, analysts anticipate that the firm will report sales of $415.53 million per share, with estimates ranging from $407.20 million to $420.80 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Medpace.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, October 30th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The firm had revenue of $98.68 million during the quarter, compared to analysts’ expectations of $96.84 million. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.40 earnings per share.
MEDP has been the topic of several research reports. Zacks Investment Research upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Friday, November 3rd. BidaskClub upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Jefferies Group lifted their target price on Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a report on Wednesday, November 1st. KeyCorp reaffirmed a “hold” rating on shares of Medpace in a report on Tuesday, October 17th. Finally, Robert W. Baird reaffirmed a “hold” rating and set a $32.00 target price on shares of Medpace in a report on Monday, October 9th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $36.60.
Shares of Medpace (MEDP) traded down $0.27 during mid-day trading on Friday, hitting $36.26. 122,063 shares of the stock traded hands, compared to its average volume of 193,045. The stock has a market cap of $1,382.23, a price-to-earnings ratio of 53.32, a P/E/G ratio of 1.88 and a beta of -0.96. Medpace has a 1-year low of $21.76 and a 1-year high of $39.64. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68.
In other news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of Medpace stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total transaction of $138,736,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 25.80% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. First Quadrant L P CA acquired a new stake in Medpace in the 3rd quarter worth approximately $119,000. Susquehanna International Group LLP bought a new stake in shares of Medpace during the second quarter valued at approximately $220,000. Credit Suisse AG bought a new stake in shares of Medpace during the first quarter valued at approximately $231,000. Rhumbline Advisers increased its position in shares of Medpace by 13.3% during the second quarter. Rhumbline Advisers now owns 9,726 shares of the company’s stock valued at $282,000 after purchasing an additional 1,140 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in shares of Medpace during the second quarter valued at approximately $299,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “$97.43 Million in Sales Expected for Medpace Holdings Inc (MEDP) This Quarter” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/97-43-million-in-sales-expected-for-medpace-holdings-inc-medp-this-quarter.html.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Get a free copy of the Zacks research report on Medpace (MEDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.